Q2 2018 Data Report

This report assembles a global sector overview, including details on financings, partnerships and other deals, clinical trial information, major clinical data events, and ARM’s current legislative and regulatory priorities.

This report assembles a global sector overview, including details on financings, partnerships and other deals, clinical trial information, major clinical data events, and ARM’s current legislative and regulatory priorities.

Back to Publications

Global Landscape

875+

Regenerative Medicine Companies
Worldwide, Including Gene and
Cell Therapies, and Tissue Engineering
Therapeutic Developers

466North America23Oceania1Africa135Asia15South America235Europe & Israel

Financings

Total Q2 2018 Global Financings

Total Global Financing

$4.1 Billion

164%

Increase from Q2 2017

35.3%64.7%0144.555.566.577.5Q2 2018Full Year 2017

79%

Increase year-over-year
$7.9B Raised YTD 2018

Gene & Gene-modified
Cell Therapy

$2.7 Billion

 124%

Increase from Q2 2017

37.5%62.5%012.62.833.23.43.63.844.24.44.6Q2 2018Full Year 2017

133%

Increase year-over-year
$5.8B raised YTD 2018

Cell Therapy

$2.2 Billion

416%

Increase from Q2 2017

35.5%64.5%012.22.42.62.833.23.43.63.84Q2 2018Full Year 2017

83%

Increase year-over-year
$4.2B raised YTD 2018

Tissue Engineering

$421 Million

526%

Increase from Q2 2017

48.6%51.4%01420422424426428430432434436438440442444446448Q2 2018Full Year 2017

25%

Increase year-over-year
$784M raised YTD 2018

Total Global Financings by Type, by Year

913.42800913.61900680.2254398011001400657.5587.6884647.21300883.6IPOsFollow-OnsCorporatePartnershipsVenture CapitalPrivatePlacement /PIPES0$500m$1,000m$1,500m$2,000m$2,500m$3,000m$3,500m$4,000m$4,500m$5,000m1H 2018Full Year 2017Full Year 2016
17800135001050Mergers &Acquisitions0$2,000m$4,000m$6,000m$8,000m$10,000m$12,000m$14,000m$16,000m$18,000m$20,000m$22,000m1H 2018Full Year 2017Full Year 2016

977

Clinical trials underway
worldwide by the end of Q2 2018

PH. 1

324

PH. 2

560

PH. 3

93

33.2%57.3%9.5%050100150200250300350400450500550600Phase 1Phase 2Phase 3

Clinical Trials

Number of Clinical Trials Utilizing Specific
RM / AT Technology:

Q2 2018

Gene Therapy
34.4%54.9%10.7%020406080100120140160180Phase IPhase IIPhase III
Gene-Modified
Cell Therapy
42.7%52.9%0020406080100120140160180Phase IPhase IIPhase III
Cell Therapy
23.6%64.6%11.8%0406080100120140160180200220Phase IPhase IIPhase III
Tissue Engineering
20.8%50.0%29.2%056789101112Phase IPhase IIPhase III

Clinical Trials by Indication: Q2 2018

Oncology
532
Cardiovascular
74
Musculoskeletal
61
Central Nervous System
56
Endocrine Metabolic & Genetic Disorders
38
Dermatology
37
Hematology
36
Immunology & Inflammation
34
Ophthalmology
34
Infectious Disease
27
Genitourinary Disorders
13
Gastroenterology
13
Respiratory
10
Surgery
4
Lymphatic Diseases
3
Ear Diseases
2
Geriatric Diseases
2
Radiation Injury
1

Report Infographics

View Full Report View Past Reports

Alliance for Regenerative Medicine

CONTACT

1015 18th Street NW
Suite 1102
Washington, D.C. 20036

info@alliancerm.org

2-4 Schuman Roundabout
B-1040 Brussels
Belgium